The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations
Abstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) h...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | Chinese Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13020-021-00483-6 |
id |
doaj-9952cb39dc584cd599bc4a9a20274096 |
---|---|
record_format |
Article |
spelling |
doaj-9952cb39dc584cd599bc4a9a202740962021-08-08T11:09:09ZengBMCChinese Medicine1749-85462021-08-0116111410.1186/s13020-021-00483-6The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparationsHua Luo0Hongguo Chen1Chang Liu2Siyuan Zhang3Chi Teng Vong4Dechao Tan5Yuntao Dai6Yitao Wang7Shilin Chen8Macau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauKey Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical SciencesMacau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of MacauKey Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical SciencesAbstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) has aroused profound impetus in the investigation of TCM and attracted global attention to the ancient books of TCM. Three new medicines for the treatment of COVID-19 derived from Chinese Classical Formula (经典名方, CCF) have been approved in 2021 due to their effectiveness for the treatment of COVID-19. This article introduced the research background of CCF pharmaceutical preparation (CCFPP), explained the ideas for the modernization of CCF and analyzed related issues involved in the development process of CCFPP, including the origin of medicinal materials, processing methods, dosages and the preparation process of CCF Material Reference. The strategy for industrialization was proposed in terms of the evaluation of the pharmaceutical properties, industrialization considerations, and clinical positioning of CCFPP. The key contents and requirements for the development CCFPP were also summarized according to the recently published registration guidance by the Center for Drug Evaluation in China. In addition, the safety issues of CCFPP were described, including the discussion on the non-clinical safety evaluation and analyzation on the international registration of Traditional herbal medicines. This article is aimed to provide references for enterprises, researchers, and relevant personnel of government departments that are engaged in the development of CCF to speed up the developing process of CCFPP.https://doi.org/10.1186/s13020-021-00483-6Chinese Classical FormulasMaterial ReferenceOrigin of the medicinal materialsProcessing methodsDosage verificationQuality control |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hua Luo Hongguo Chen Chang Liu Siyuan Zhang Chi Teng Vong Dechao Tan Yuntao Dai Yitao Wang Shilin Chen |
spellingShingle |
Hua Luo Hongguo Chen Chang Liu Siyuan Zhang Chi Teng Vong Dechao Tan Yuntao Dai Yitao Wang Shilin Chen The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations Chinese Medicine Chinese Classical Formulas Material Reference Origin of the medicinal materials Processing methods Dosage verification Quality control |
author_facet |
Hua Luo Hongguo Chen Chang Liu Siyuan Zhang Chi Teng Vong Dechao Tan Yuntao Dai Yitao Wang Shilin Chen |
author_sort |
Hua Luo |
title |
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations |
title_short |
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations |
title_full |
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations |
title_fullStr |
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations |
title_full_unstemmed |
The key issues and development strategy of Chinese Classical Formulas pharmaceutical preparations |
title_sort |
key issues and development strategy of chinese classical formulas pharmaceutical preparations |
publisher |
BMC |
series |
Chinese Medicine |
issn |
1749-8546 |
publishDate |
2021-08-01 |
description |
Abstract It is well-known that Prof. Tu Youyou won the Nobel Prize in Physiology or Medicine in 2015 due to the research on artemisinin treating malaria, and this can be regarded as the milestone of modernization of Traditional medicine. This first Nobel Prize in Traditional Chinese medicine (TCM) has aroused profound impetus in the investigation of TCM and attracted global attention to the ancient books of TCM. Three new medicines for the treatment of COVID-19 derived from Chinese Classical Formula (经典名方, CCF) have been approved in 2021 due to their effectiveness for the treatment of COVID-19. This article introduced the research background of CCF pharmaceutical preparation (CCFPP), explained the ideas for the modernization of CCF and analyzed related issues involved in the development process of CCFPP, including the origin of medicinal materials, processing methods, dosages and the preparation process of CCF Material Reference. The strategy for industrialization was proposed in terms of the evaluation of the pharmaceutical properties, industrialization considerations, and clinical positioning of CCFPP. The key contents and requirements for the development CCFPP were also summarized according to the recently published registration guidance by the Center for Drug Evaluation in China. In addition, the safety issues of CCFPP were described, including the discussion on the non-clinical safety evaluation and analyzation on the international registration of Traditional herbal medicines. This article is aimed to provide references for enterprises, researchers, and relevant personnel of government departments that are engaged in the development of CCF to speed up the developing process of CCFPP. |
topic |
Chinese Classical Formulas Material Reference Origin of the medicinal materials Processing methods Dosage verification Quality control |
url |
https://doi.org/10.1186/s13020-021-00483-6 |
work_keys_str_mv |
AT hualuo thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT hongguochen thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT changliu thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT siyuanzhang thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT chitengvong thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT dechaotan thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT yuntaodai thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT yitaowang thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT shilinchen thekeyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT hualuo keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT hongguochen keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT changliu keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT siyuanzhang keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT chitengvong keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT dechaotan keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT yuntaodai keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT yitaowang keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations AT shilinchen keyissuesanddevelopmentstrategyofchineseclassicalformulaspharmaceuticalpreparations |
_version_ |
1721216300450054144 |